App-Quantinova.ai

High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting.

Kelly Lehner - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Solid malignancies

Docetaxel

A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).

Irbaz Bin Riaz - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Elias Chandran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Effect of neuroendocrine differentiation on therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.

Nanwei Xu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Adam B Weiner - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Long-term taxane exposure and transdifferentiation of prostate cancer in vitro.

Gunhild Von Amsberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.

Sachdev P. Thomas - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.

Manish Kohli - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

Shahneen Sandhu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial.

Pedro H Isaacsson Velho - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Louise Kathleen Kostos - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

Simon J. Crabb - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Umang Swami - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Arun Azad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Docetaxel

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.

Tamim Niazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin for the treatment of high-risk, treatment-naïve, non-muscle invasive bladder cancer.

Ian M. McElree - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Docetaxel

Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.

Sunil H. Patel - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Docetaxel

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Sarmad Sadeghi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Docetaxel

Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab

Khaled Tolba - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Filters

2459 Abstracts